Introduction {#s1}
============

The [Reproducibility Project: Cancer Biology](https://osf.io/e81xl/wiki/home/) (RP:CB) is a collaboration between the [Center for Open Science](https://cos.io/) and [Science Exchange](https://www.scienceexchange.com/) that seeks to address concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology ([@bib13]). For each of these papers a Registered Report detailing the proposed experimental designs and protocols for the replications was peer reviewed and published prior to data collection. The present paper is a Replication Study that reports the results of the replication experiments detailed in the Registered Report ([@bib18]), for a paper by Dawson et al., and uses a number of approaches to compare the outcomes of the original experiments and the replications.

In 2011, Dawson et al. demonstrated targeting BET proteins as an effective strategy for modulating aberrant gene expression associated with mixed-lineage leukaemia (MLL), a genetically distinct form of acute leukaemia. Selective inhibition of cell viability and *BCL2* expression in leukaemia cells harboring MLL fusions was observed with the BET bromodomain inhibitor, I-BET151, in contrast to leukaemia cells with alternate oncogenic drivers ([@bib11]). Furthermore, efficacy of I-BET151 was tested in a xenograft model of MLL, which resulted in a statistically significant increase in survival compared to vehicle control treated animals.

The Registered Report for the paper by Dawson et al. described the experiments to be replicated (Figures 2A, 3D, 4B and D, and Supplementary Figures 11A-B and 16A), and summarized the current evidence for these findings ([@bib18]). Recent studies have investigated the efficacy of targeting BET bromodomains in other cancer types. Studies using structurally distinct BET inhibitors, JQ1 and OTX015, have reported these inhibitors to be highly active in various cell lines, mouse models, and primary patient samples of MLL and other types of AML ([@bib5]; [@bib8]; [@bib14]; [@bib23]; [@bib33]; [@bib54]). Furthermore, I-BET151 was reported to be active against AML with mutations involving the nucleophosmin (*NPM1*) gene (NPM1c AML) ([@bib10]). Additional studies examining the antitumor effects of BET bromodomain inhibition include other cancer types, such as gastric cancer ([@bib34]), childhood sarcoma ([@bib3]), triple negative breast cancer ([@bib9]; [@bib45]), and ovarian cancer ([@bib53]). Additionally, evidence indicating potential acquired resistance to BET inhibitors has been reported ([@bib15]; [@bib28]; [@bib39]), along with studies which have found that treatment with combinatorial drugs can mitigate acquired resistance ([@bib2]; [@bib29]; [@bib52]). Furthermore, a recent study reported synergistic effects of combinatorial treatment with a disruptor of telomeric silencing 1-like (DOT1L) inhibitor and I-BET151 in MLL cells and mouse leukaemia models ([@bib20]). Studies have also addressed the nonclinical safety of BET inhibition and found that BET bromodomain inhibition can impact normal intestinal homeostasis and repair ([@bib35]). There are several variations of I-BET bromodomain inhibitors currently in clinical trials ([@bib4]; [@bib16]; [@bib50]). A phase I trial to determine the recommended dose of BET inhibitor OTX015/MK-8628 reported that although the inhibitor was found to be tolerated, toxic effects such as thrombocytopenia were commonly observed ([@bib1]). An additional clinical study testing BET inhibition with OTX015/MK-8628 in four patients with advanced NUT midline carcinoma, with confirmed BRD4-NUT fusions, found early clinical benefits reported for two patients with one achieving post-treatment disease stabilization ([@bib47]).

The outcome measures reported in this Replication Study will be aggregated with those from the other Replication Studies to create a dataset that will be examined to provide evidence about reproducibility of cancer biology research, and to identify factors that influence reproducibility more generally.

Results and discussion {#s2}
======================

Evaluating the selective inhibition of a MLL-fusion leukaemic cell line with I-BET151 {#s2-1}
-------------------------------------------------------------------------------------

Using the same BET bromodomain inhibitor as Dawson et al., we aimed to independently replicate an experiment analyzing the ability of I-BET151 to selectively inhibit the growth of the MLL-fusion leukaemic cell line MV4;11 (MLL-AF4 fusion). Similar to the original study, the K-562 leukaemic cell line, which is oncogenically driven by tyrosine kinase activation, served as a negative control. This experiment is comparable to what was reported in Figure 2A and Supplementary Figure 11A-B of [@bib11] and described in Protocols 1--2 in the Registered Report ([@bib18]). While the original study included a variety of human leukaemia cell lines, this replication attempt was restricted to the MV4;11 and K-562 cell lines, which were utilized in further experiments. For each cell line, cellular IC~50~ values were determined ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) with a mean absolute IC~50~ value of 9.03 nM \[n = 5, *SD* = 8.27 nM\] for I-BET151 treated MV4;11 cells, while the K-562 IC~50~ estimates were not able to be accurately determined following published guidelines ([@bib43]). This compares to the original study that reported an IC~50~ value of 26 nM for MV4;11 cells, with the K-562 IC~50~ value also unable to be accurately determined ([@bib11]).10.7554/eLife.25306.002Figure 1.Cellular I-BET151 dose response curves in MLL-fusion leukaemia and non-MLL-fusion leukaemia cell lines.Cell viability assays were performed for a MLL-fusion leukaemia cell line (MV4;11) and a non-MLL-fusion leukaemia cell line (K-562) with the I-BET151 inhibitor. Curves and absolute IC~50~ values were determined for each biological repeat. (**A**) Dose response curves for each biological repeat \[n = 5\] for the MV4;11 cell line. Percent cell viability is relative to DMSO treated cells. I-BET151 doses range from 1 pM to 1 mM. Exploratory one-sample *t*-test of IC~50~ values compared to a constant of 100 µM; *t*(4) = 20.63, *p*=3.26×10^−5^; Cohen's *d* = 9.23, 95% CI \[3.13, 15.45\]. (**B**) The mean absolute IC~50~ value for MV4;11 cells and 95% confidence interval \[n = 5\] for this replication attempt is plotted with the IC~50~ value reported in [@bib11] displayed as a single point (red circle) for comparison. (**C**) Dose response curves for each biological repeat \[n = 4\] for the K-562 cell line. Percent cell viability is relative to DMSO treated cells with I-BET151 dose range from 1 pM to 1 mM. The IC~50~ estimates were not able to be accurately determined following published guidelines ([@bib43]). Additional details for this experiment can be found at <https://osf.io/zm3j4/>.**DOI:** [http://dx.doi.org/10.7554/eLife.25306.002](10.7554/eLife.25306.002)10.7554/eLife.25306.003Figure 1---figure supplement 1.Cellular I-BET151 dose response curves for each MV4;11 biological repeat.This is the same experiment as in [Figure 1](#fig1){ref-type="fig"}. The dose response curve of each biological repeat for the MV4;11 cell line plotted individually with the absolute IC~50~ value listed. Additional details for this experiment can be found at <https://osf.io/zm3j4/>.**DOI:** [http://dx.doi.org/10.7554/eLife.25306.003](10.7554/eLife.25306.003)10.7554/eLife.25306.004Figure 1---figure supplement 2.Cellular I-BET151 dose response curves for each K-562 biological repeat.This is the same experiment as in [Figure 1](#fig1){ref-type="fig"}. The dose response curve of each biological repeat for the K-562 cell line plotted individually. The IC~50~ estimates were not able to be accurately determined following published guidelines ([@bib43]), and are listed as greater than 100 µM, which is the highest dose before inhibition started to be observed. Additional details for this experiment can be found at <https://osf.io/zm3j4/>.**DOI:** [http://dx.doi.org/10.7554/eLife.25306.004](10.7554/eLife.25306.004)

The analysis plan specified in the Registered Report ([@bib18]) proposed to compare the IC~50~ values from MV4;11 cells to those determined for K-562 cells. However, as stated above this could not be performed because of the inability to determine the K-562 IC~50~ values. Instead, we performed an exploratory analysis using the MV4;11 IC~50~ values compared to a constant of 100 µM, the highest dose in K-562 cells before inhibition started to be observed, which was statistically significant (one-sample *t*-test; *t*(4) = 20.63, *p*=3.26×10^−5^; Cohen's *d* = 9.23, 95% CI \[3.13, 15.45\]). To summarize, for this experiment we found results that were in the same direction as the original study and statistically significant where predicted.

Analysis of *BCL2* gene expression following I-BET151 treatment {#s2-2}
---------------------------------------------------------------

A key antiapoptotic gene, *BCL2*, which has been implicated in MLL-fusion leukaemias ([@bib41]; [@bib51]), was reported in [@bib11] to be selectively inhibited by I-BET151, suggesting a possible mode of action. We sought to replicate this experiment, which is similar to what was reported in Figure 3D of [@bib11] and described in Protocol 3 in the Registered Report ([@bib18]). While the original study included multiple leukaemia cell lines with an MLL-fusion, this replication attempt was restricted to the MV4;11 cell line, which was utilized in other experiments. Similar to the cellular IC~50~ experiment, the K-562 cell line served as a control for the specificity towards MLL-fusion leukaemias. We used quantitative real-time-polymerase chain reaction (qRT-PCR) to assess *BCL2* expression in MV4;11 and K-562 cells treated with I-BET151 or vehicle control ([Figure 2](#fig2){ref-type="fig"}). Using the 2^-∆∆Ct^ method, treatment of MV4;11 cells with I-BET151 resulted in a 0.501 \[n = 3, *SD* = 0.048\] mean fold change in *BCL2* expression relative to vehicle control, while K-562 cells remained largely unchanged \[n = 3, M = 1.06, *SD* = 0.028\]. This is similar to [@bib11], which reported an \~0.22 mean fold change in *BCL2* expression for MV4;11 cells and an \~0.94 mean fold change for the K-562 cell line.10.7554/eLife.25306.005Figure 2.*BCL2* expression in I-BET151 treated MV4;11 and K-562 cells.MV4;11 and K-562 cells were treated with 500 nM I-BET151, or an equivalent volume of DMSO. Total RNA was isolated 6 hr after treatment and qRT-PCR was used to detect *BCL2* and *B2M* expression. Fold change in *BCL2* expression normalized to *B2M* and relative to DMSO is presented for I-BET151 treated MV4;11 and K-562 cells. Expression level of *BCL2* in DMSO was assigned a value of 1. Means reported and error bars represent *SD* from three independent biological repeats. Two-sample *t*-test comparing fold gene expression values from MV4;11 cells to K-562 cells; *t*(4) = 17.23, uncorrected *p*=6.66×10^−5^, *a priori* Bonferroni adjusted significance threshold = 0.0167; (Bonferroni corrected *p*=0.0004). One-sample *t*-test comparing fold gene expression from K-562 cells to a constant of 1 (DMSO treated cells); *t*(2) = 3.53, uncorrected *p*=0.0719, *a priori* Bonferroni adjusted significance threshold = 0.0167; (Bonferroni corrected *p*=0.216). One-sample *t*-test comparing fold gene expression from MV4;11 cells to a constant of 1 (DMSO treated cells); *t*(2) = 17.86, uncorrected *p*=0.003, *a priori* Bonferroni adjusted significance threshold = 0.0167; (Bonferroni corrected *p*=0.009). Additional details for this experiment can be found at <https://osf.io/np6gq/>.**DOI:** [http://dx.doi.org/10.7554/eLife.25306.005](10.7554/eLife.25306.005)

To provide a direct comparison to the original data, we are reporting the analysis specified *a priori* in the Registered Report ([@bib18]). We planned to conduct one two-sample *t*-test, between K-562 and MV4;11 fold gene expression values, and two one-sample *t*-tests, on K-562, or MV4;11, fold gene expression values compared to a constant of 1, which represents the DMSO treated gene expression. To account for these multiple comparisons, the Bonferroni correction was used, making the *a priori* Bonferroni adjusted significance threshold 0.0167. We performed an unpaired, two-sample *t*-test on the fold gene expression values from K-562 cells compared to MV4;11 cells, which was statistically significant (*t*(4) = 17.23, uncorrected *p*=6.66×10^−5^, corrected *p*=0.0004). Thus, the null hypothesis that I-BET151 treatment on *BCL2* expression is similar for MV4;11 and K-562 cells can be rejected. Additionally, we performed a one-sample *t*-test on the fold gene expression values from K-562 cells compared to a constant of 1 (*t*(2) = 3.53, uncorrected *p*=0.072, corrected *p*=0.216), and a one-sample *t*-test on the fold gene expression values from MV4;11 cells compared to a constant of 1 (*t*(2) = 17.86, uncorrected *p*=0.003, corrected *p*=0.009). To summarize, for this experiment we found results that were statistically significant where predicted and in the same direction as the original study.

Generation of disseminated xenograft MLL mouse model and testing of I-BET151 compound *in vivo* {#s2-3}
-----------------------------------------------------------------------------------------------

In order to test the efficacy of I-BET151 as a therapeutic agent in MLL-fusion leukaemia, we sought to replicate an experiment similar to what was reported in Figure 4B and D and Supplementary Figure 16A ([@bib11]) and described in Protocols 4--5 in the Registered Report ([@bib18]). Prior to conducting this efficacy experiment, we determined the maximum tolerated dose (MTD) of I-BET151 in this xenograft mouse model, which imitates the pathology of human leukaemia by disseminating to the bone marrow ([@bib30]). Five weeks after intravenous injection of MV4;11 cells into 7-week-old female NOD-SCID mice, the animals were successfully engrafted as determined by detectable human leukaemia cells in the peripheral blood. This was an increase from the 3 weeks reported in the original study, but was necessary due to the lack of detectable leukaemia cells in mice at 3 weeks post-injection during this replication attempt. Mice were randomized into treatment groups and after 21 days of daily intraperitoneal (IP) injections of vehicle control or three different doses of I-BET151, the MTD was determined as 20 mg/kg/day ([Figure 3](#fig3){ref-type="fig"}) based on the criteria pre-specified in the Registered Report ([@bib18]). For comparison the original study delivered I-BET151 daily at 30 mg/kg. While it is not uncommon for variations in stock solution to cause differing compound potency and toxicity ([@bib25]), a reduced dose could have an impact on I-BET151 efficacy. Indeed, recent work from authors of the original study reported I-BET151 administered at 10 mg/kg had no impact on survival in a MLL-AF9 leukaemia mouse model ([@bib20]), while I-BET151 administered at 15 mg/kg did provide a survival benefit in a mouse model of NPM1c AML, albeit with a smaller effect size ([@bib10]).10.7554/eLife.25306.006Figure 3.Maximal tolerated dose in an I-BET151 treated xenograft mouse model of MLL-fusion leukaemia.Female NOD-SCID mice were conditioned with Busulfan and intravenously injected with 1 × 10^7^ MV4;11 cells in vehicle (PBS). Once disease was established (detectable MV4;11 cells from retro-orbital bleeds), mice were randomized into four cohorts and received daily IP injections of vehicle control \[n = 5\], 10 mg/kg I-BET151 \[n = 5\], 20 mg/kg I-BET151 \[n = 5\], or 30 mg/kg I-BET151 \[n = 5\]. The animals were monitored and their weight was measured for the duration of the 21 day treatment. The Y axis represents mouse weight in grams, the X axis represents days since the start of treatment. Additional information can be found at <https://osf.io/juzmg/>.**DOI:** [http://dx.doi.org/10.7554/eLife.25306.006](10.7554/eLife.25306.006)10.7554/eLife.25306.007Figure 3---figure supplement 1.Maximal tolerated dose in an I-BET151 treated xenograft mouse model of MLL-fusion leukaemia.This is the same experiment as in [Figure 3](#fig3){ref-type="fig"}. Female NOD-SCID mice xenotransplanted with MV4;11 cells were randomly assigned to receive daily IP injections of treatment. At the time of sacrifice, disease burden was evaluated in peripheral blood (PB), bone marrow (BM), and spleen cells. Number of mice analyzed: n = 5 for vehicle group, n = 5 for I-BET151 10 mg/kg group, n = 5 for I-BET151 20 mg/kg, and n = 5 for I-BET151 30 mg/kg. (**A**) Dot plot representing the percent of MV4;11 as the percent of HLA-A,B,C^+^ cells determined by flow cytometry analyses of the total cell population. Medians reported as crossbars. (**B**) Dot plot representing the absolute number of MV4;11 cells as determined using CountBright absolute counting beads. Medians reported as crossbars. Additional details for this experiment can be found at <https://osf.io/juzmg/>.**DOI:** [http://dx.doi.org/10.7554/eLife.25306.007](10.7554/eLife.25306.007)

Following the same procedure as the MTD protocol, another cohort of 7-week-old female NOD-SCID mice were injected with MV4;11 cells and monitored until engraftment was established, which also occurred 5 weeks after injection. Mice were treated daily with I-BET151 at 20 mg/kg or vehicle control by IP injection for up to 21 days or until mice were humanely euthanized at signs of distress or disease (e.g. hind limb paralysis). At the time of sacrifice, disease presence was determined by evaluating the percentage of human leukaemia cells present in the peripheral blood, spleen, and bone marrow ([Figure 4B](#fig4){ref-type="fig"}). Disease was defined, *a priori*, as 0.5% of human leukaemia cells over the total live nucleated cells, which included human and mouse cells, in the sample. After the start of treatment, mice treated with vehicle control achieved a median survival of 19.0 days \[n = 11\], which is indistinguishable from the 18.5 days \[n = 12\] observed in mice treated with I-BET151 ([Figure 4A](#fig4){ref-type="fig"}). A planned comparison between these survival distributions using a log-rank (Mantel-Cox) test was not statistically significant (*p*=0.536). This compares to the original study that reported a median survival of 14 days, \[n = 5\] for vehicle control treated animals that was lengthened to the experimental end-point of 21 days with I-BET151 treatment. While the median survival after the start of treatment in control treated mice are similar between these studies, the overall median survival from the MV4;11 injection are farther apart, with the original study reporting a median time of 35 days and this replication attempt reporting 59 days due to the added time from injection to beginning of treatment. Comparatively, other published studies using this model have reported a range of median survival times, such as 41 days ([@bib36]), 51 days ([@bib12]; [@bib30]; [@bib31]), and 60 days ([@bib22]) after intravenous injection of MV4;11 cells into NOD-SCID mice. To summarize, for this experiment we found the survival results were not in the same direction as the original study and not statistically significant where predicted.10.7554/eLife.25306.008Figure 4.Efficacy study of I-BET151 in xenograft mouse model of MLL-fusion leukaemia.Female NOD-SCID mice were xenotransplanted with 1 × 10^7^ MV4;11 cells after conditioning with Busulfan. Following establishment of disease (detectable MV4;11 cells from retro-orbital bleeds), mice were randomly assigned to receive daily IP injections of 20 mg/kg I-BET151 or vehicle control. (**A**) Kaplan-Meier plot of survival during the course of the study. Green arrowhead indicates when treatment commenced on day 40 with treatment continuing for the pre-specified period of 21 days. Animals with no detectable disease at the time of sacrifice (less than 0.5% of MV4;11 cells) or that were unable to be evaluated at the time of death were censored (denoted by a cross). Number of mice monitored: n = 11 for vehicle group and n = 12 for I-BET151 group. Log-rank (Mantel-Cox) test of I-BET151 treatment compared to vehicle control (*p*=0.536). (**B--C**) At the time of sacrifice, disease burden was evaluated in peripheral blood (PB), bone marrow (BM), and spleen cells. Number of mice analyzed: n = 8 for vehicle group and n = 10 for I-BET151 group. (**B**) The percent of MV4;11 cells was determined by flow cytometric analysis as the percent of HLA-A,B,C^+^ cells in the total nucleated population (both mouse and human cells). Dot plot with medians reported as crossbars. (**C**) The absolute number of MV4;11 cells each sample was also determined using CountBright absolute counting beads. Dot plot with medians reported as crossbars. Additional details for this experiment can be found at <https://osf.io/jakpw/>.**DOI:** [http://dx.doi.org/10.7554/eLife.25306.008](10.7554/eLife.25306.008)10.7554/eLife.25306.009Figure 4---figure supplement 1.Mouse body weight and cell death analysis in I-BET151 treated xenograft mouse model of MLL-fusion leukaemia.This is the same experiment as in [Figure 4](#fig4){ref-type="fig"}. Female NOD-SCID mice xenotransplanted with MV4;11 cells were randomly assigned to receive daily IP injections of 20 mg/kg I-BET151 or vehicle control after detection of disease. (**A**) During the course of treatment animals were monitored and their weight was measured twice a week over the 21 day treatment period. Number of mice monitored: n = 11 for vehicle group and n = 12 for I-BET151 group. (**B--C**) At the time of sacrifice, cell death (apoptotic and necrotic cells) was evaluated in peripheral blood (PB), bone marrow (BM), and spleen cells. Number of mice analyzed: PB: n = 4 for vehicle group and n = 7 for I-BET151 group; BM: n = 6 for vehicle group and n = 8 for I-BET151 group; Spleen: n = 6 for vehicle group and n = 8 for I-BET151 group. (**B**) The percent of MV4;11 cells that were apoptotic was determined by flow cytometric analysis as the percent of Annexin V^+^PI^-^ cells in the HLA-A,B,C^+^ population. Dot plot with medians reported as crossbars. (**C**) The percent of MV4;11 cells that were necrotic was determined by flow cytometric analysis as the percent of Annexin V^+^PI^+^ cells in the HLA-A,B,C^+^ population. Dot plot with medians reported as crossbars. Additional details for this experiment can be found at <https://osf.io/jakpw/>.**DOI:** [http://dx.doi.org/10.7554/eLife.25306.009](10.7554/eLife.25306.009)10.7554/eLife.25306.010Figure 4---figure supplement 2.Detection of HLA by immunohistochemistry in mouse tissues.This is from the same experiment as in [Figure 4](#fig4){ref-type="fig"}. Female NOD-SCID mice xenotransplanted with MV4;11 cells were randomly assigned to receive daily IP injections of 20 mg/kg I-BET151 or vehicle control after detection of disease. Tissues containing observed tumors were fixed, sectioned, and stained with an antibody against human leukocyte antigen (HLA-A,B,C) and counterstained with hematoxylin. (**A**) Positive control staining of human tonsil tissue that was processed in parallel with other tissue sections (magnification: 400X left, 100X right). Representative images of various tissues from MV4;11 engrafted mice who received vehicle treatment, which include (**B**) stomach (magnification: 400X left, 100X right), (**C**) gastrointestinal tract (magnification: 400X left, 100X right), (**D**) mesentery (magnification: 400X left, 20X right), (**E**) ovary (magnification: 400X left, 20X right), and (**F**) peritoneal cavity (magnification: 400X). Mouse tissues (e.g. gastrointestinal mucosa) were negatively stained. Additional details for this experiment can be found at <https://osf.io/jakpw/>.**DOI:** [http://dx.doi.org/10.7554/eLife.25306.010](10.7554/eLife.25306.010)10.7554/eLife.25306.011Figure 4---figure supplement 3.Flow cytometry gating strategies.(**A**) Representative images of gating strategy to assess leukaemia burden in peripheral blood, spleen, and bone marrow cells. The FL-3 vs FSC plot was used to gate on CountBright absolute counting beads and total nucleated cells. From the total nucleated population, the HLA-A,B,C APC vs FSC plot was used to gate on HLA-A,B,C^+^ cells (human leukaemia cells). (**B**) Representative images of gating strategy to assess cell death in peripheral blood, spleen, and bone marrow cells. The HLA-A,B,C APC vs FSC plot was used to gate on human leukaemia cells. From the human leukaemia cell population, the PI vs Annexin V FITC plot was used to gate on apoptotic cells (Annexin V^+^PI^−^ population) and necrotic cells (Annexin V^+^PI^+^ population).**DOI:** [http://dx.doi.org/10.7554/eLife.25306.011](10.7554/eLife.25306.011)

In addition to monitoring survival, disease burden was determined for vehicle control and I-BET151 treated mice. For the efficacy study, the median disease burden observed in the peripheral blood, bone marrow, and spleen were smaller in I-BET151 treated mice compared to the control mice ([Figure 4B,C](#fig4){ref-type="fig"}). This was also observed in the MTD study ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). For example, the median percent of leukaemia cells detected in the bone marrow of vehicle control mice was 10.7%, which was reduced to 5.3% in I-BET151 treated mice ([Figure 4B](#fig4){ref-type="fig"}). This compares to the representative example reported in Supplementary Figure 16A of [@bib11], which reported 14% leukaemia burden in the bone marrow of the control mouse and 1.5% in the I-BET151 treated mouse where low-level residual leukaemia was reported after the 21 day treatment. To summarize, for the disease burden aspect of this experiment we found the results were in the same direction as the original study.

To assess if I-BET151 impacted cell death, specifically apoptosis and necrosis, flow cytometric analysis was also performed on the isolated cells from the vehicle control or I-BET151 treated mice. The degree of apoptosis and necrosis was assessed within the leukaemia population by staining with Annexin V and propidium iodide (PI). Observationally, there was no notable difference in the peripheral blood or spleen, with a minor decrease in both apoptotic (Annexin V+PI-) and necrotic cells (Annexin V+PI+) observed in the bone marrow of I-BET151 treated mice compared to vehicle control ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

Unexpectedly, at the time of sacrifice, animal health issues were observed beyond the anticipated disease presentation for this model. These included gastrointestinal bloating in three of the I-BET151 treated mice and solid tumors detected in four of the vehicle control treated mice and two of the I-BET151 treated mice. While it has been previously noted that NOD-SCID mice have a high rate of spontaneous thymic lymphomas, no other tumor types were previously reported and tumors did not manifest until 20 weeks of age ([@bib37]). To explore the origin of the observed tumors, sections were stained using a human leukocyte antigen (HLA-A,B,C) antibody ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). In all tested samples there was extensive staining, indicating the injected human leukaemia cells spread throughout the mouse outside the hematological tissues. This suggests these mice most likely succumbed to fulminant leukaemia manifesting often as extramedullary disease (EMD), a diagnosis that has been observed in a subset of patients with various types of AML ([@bib19]). Indeed, the original study reported EMD in the majority of the control mice, in contrast to none of the I-BET151 treated mice ([@bib11]). Collectively, these observations raise the possibility that although a survival benefit was not observed with I-BET151 treatment in this replication attempt, despite an overall reduced disease burden, that health issues not directly related to leukaemia could have impacted mortality observed in some of the animals, particularly those treated with I-BET151. Additionally, busulfan conditioning could have influenced engraftment kinetics and disease progression in this animal model and potentially impacted the responsiveness of MV4;11 cells to I-BET151 treatment.

Meta-analyses of original and replicated effects {#s2-4}
------------------------------------------------

We performed a meta-analysis using a random-effects model, where possible, to combine each of the effects described above as pre-specified in the confirmatory analysis plan ([@bib18]). To provide a standardized measure of the effect, a common effect size was calculated for each effect from the original and replication studies. Cohen's *d* is the standardized difference between two independent means using the pooled sample standard deviation. For a one-sample test, Cohen's *d* is the difference between the sample mean and the null value using the sample standard deviation. The hazard ratio (HR) is the ratio of the probability of a particular event, in this case death, in one group compared to the probability in another group. The estimate of the effect size of one study, as well as the associated uncertainty (i.e. confidence interval), compared to the effect size of the other study provides another approach to compare the original and replication results ([@bib13]; [@bib48]). Importantly, the width of the confidence interval for each study is a reflection of not only the confidence level (e.g. 95%), but also variability of the sample (e.g. *SD*) and sample size.

A meta-analysis of the I-BET151 IC~50~ values in MV4;11 and K-562 cells was not conducted since the original study reported single IC~50~ values. Comparing the original and replication results, the IC~50~ value reported in [@bib11] for MV4;11 cells fell outside the 95% CI of the values generated during this replication attempt ([Figure 1B](#fig1){ref-type="fig"}). In K-562 cells, both the original and replication studies could not accurately determine the IC~50~ estimates indicating K-562 cells are largely unaffected by I-BET151.

There were three comparisons made with the qRT-PCR data analyzing *BCL2* expression following I-BET151 treatment ([Figure 5A,B](#fig5){ref-type="fig"}). For two of the comparisons, the fold *BCL2* expression in each cell line was compared to a constant of 1, which represents the DMSO treated group ([Figure 5A](#fig5){ref-type="fig"}). The comparison of K-562 fold gene expression compared to a constant of 1 resulted in *d* = −2.04, 95% CI \[−4.17, 0.13\] in this study, whereas *d* = 1.30, 95% CI \[−0.38, 2.88\] for the data estimated *a priori* from [Figure 3D](#fig3){ref-type="fig"} in the original study ([@bib11]). A meta-analysis of these effects resulted in *d* = −0.307, 95% CI \[−3.57,2.96\], which was not statistically significant (*p*=0.854). The results are in opposition when considering the direction of the effect. The point estimate of the replication effect size was not within the confidence interval of the original result, nor was the point estimate of the original effect size within the confidence interval of the replication result. The comparison of MV4;11 fold gene expression compared to a constant of 1, resulted in *d* = 10.31, 95% CI \[1.54, 19.86\] in this replication attempt, *d* = 26.00, 95% CI \[4.10, 48.25\] for the data estimated from the original study ([@bib11]) and *d* = 15.13, 95% CI \[0.94, 29.32\] for a meta-analysis of the two effects. Both the original and replication results are consistent when considering the direction of the effect, with the point estimate of the replication effect size was within the confidence interval of the original result and vice versa. Further, the random effects meta-analysis resulted in a statistically significant effect (*p*=0.037). For the third comparison between MV4;11 and K-562 fold gene expression, this replication attempted resulted in *d* = 14.07, 95% CI \[4.73, 23.59\], which compares to *d* = 17.34, 95% CI \[5.90, 29.04\] for the data estimated from the original study ([@bib11]) ([Figure 5B](#fig5){ref-type="fig"}). A meta-analysis of these effects resulted in *d* = 15.37, 95% CI \[5.99, 24.75\], which was statistically significant (*p*=0.001). Additionally, both results are consistent when considering the direction of the effect with both effect size point estimates falling within the confidence interval of the other study.10.7554/eLife.25306.012Figure 5.Meta-analyses of each effect.Effect size and 95% confidence interval are presented for [@bib11], this replication study (RP:CB), and a random effects meta-analysis of those two effects. Sample sizes used in [@bib11] and this replication attempt are reported under the study name. (**A**) Fold *BCL2* expression in K-562 cells compared to a constant of 1 (DMSO) (meta-analysis p=0.854), and fold *BCL2* expression in MV4;11 cells compared to a constant of 1 (DMSO) (meta-analysis p=0.037). (**B**) Fold *BCL2* expression in MV4;11 cells compared to the fold *BCL2* expression in K-562 cells (meta-analysis p=0.001). (**C**) HR for mice treated daily with I-BET151 compared to vehicle control (meta-analysis p=0.220). Additional details for these meta-analyses can be found at <https://osf.io/vfp47/.>**DOI:** [http://dx.doi.org/10.7554/eLife.25306.012](10.7554/eLife.25306.012)

The comparison of the overall survival distributions between mice treated with I-BET151 compared to those that were treated with vehicle control resulted in a HR of 1.44, 95% CI \[0.45, 4.56\] for this replication attempt compared to a HR of 10.32, 95% CI \[1.51, 70.63\] for the original study ([@bib11]). A meta-analysis ([Figure 5C](#fig5){ref-type="fig"}) of these effects resulted in a HR of 3.30, 95% CI \[0.49,22.18\], which was not statistically significant (*p*=0.220). Both results are consistent when considering the direction of the effect, however the point estimate of the replication effect size was not within the confidence interval of the original result, and vice versa. The large confidence intervals of the meta-analysis along with a statistically significant Cochran's *Q* test (*p*=0.085), suggests heterogeneity between the original and replication studies.

This direct replication provides an opportunity to understand the present evidence of these effects. Any known differences, including reagents and protocol differences, were identified prior to conducting the experimental work and described in the Registered Report ([@bib18]). However, this is limited to what was obtainable from the original paper and through communication with the original authors, which means there might be particular features of the original experimental protocol that could be critical, but unidentified. So while some aspects, such as cell lines, strain of mice, number of cells plated/injected, and specific BET inhibitor were maintained, others were changed at the time of study design ([@bib18]) or in the execution of the replication. This includes differences such as the conditioning for xenotransplantation (sub-lethal irradiation to busulfan) and dose of I-BET151 used for the efficacy study (30 mg/kg to 20 mg/kg). The regimen used in this replication attempt has not been fully evaluated with MV4;11 cells regarding its impact on disease progression and treatment responsiveness, an important consideration, since the method of conditioning can influence overall and hematological toxicity, as well as overall survival, despite similar engraftment levels ([@bib40]; [@bib42]). Furthermore, other aspects were unknown or not easily controlled for. These include variables such as cell line genetic drift ([@bib24]; [@bib26]), mouse sex ([@bib6]), circadian biological responses to therapy ([@bib17]), the microbiome of recipient mice ([@bib32]), housing temperature in mouse facilities ([@bib27]), and differing compound potency resulting from different stock solutions ([@bib25]) or from variation in cell division rates ([@bib21]). Whether these or other factors influence the outcomes of this study is open to hypothesizing and further investigation, which is facilitated by direct replications and transparent reporting.

Materials and methods {#s3}
=====================

As described in the Registered Report ([@bib18]), we attempted a replication of the experiments reported in Figures 2A, 3D, 4B and D, and Supplementary Figures 11A-B and 16A of [@bib11]. A detailed description of all protocols can be found in the Registered Report ([@bib18]). Additional detailed experimental notes, data, and analysis are available on the Open Science Framework (OSF) (RRID:[SCR_003238](https://scicrunch.org/resolver/SCR_003238)) (<https://osf.io/hcqqy/>; [@bib44]).

Cell culture {#s3-1}
------------

MV4;11 (ATCC, cat\# CRL-9591, RRID:[CVCL_0064](https://scicrunch.org/resolver/CVCL_0064)) and K-562 cells (ATCC, cat\#CCL-243, RRID:[CVCL_0004](https://scicrunch.org/resolver/CVCL_0004)) were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C in a humidified atmosphere at 5% CO~2~. Quality control data for both the MV4;11 and K-562 cell lines related to the *in vitro* experiments are available at <https://osf.io/vb9q4/> and quality control data for the MV4;11 cell line related to the *in vivo* experiments are available at <https://osf.io/5tvwe/.> This includes results confirming the cell lines were free of mycoplasma contamination and common mouse pathogens. Additionally, STR DNA profiling of the cell lines was performed and all cells were confirmed to be the indicated cell lines when queried against STR profile databases.

Therapeutic compounds {#s3-2}
---------------------

25 mg of I-BET151 (Sigma-Aldrich, cat\# SML0666; lot\# 033M4620V) was dissolved in 601.8 µl filtered dimethyl sulfoxide (DMSO) to generate a 0.1 M stock, which was stored at 4°C until use for *in vitro* experiments. For *in vivo* experiments, I-BET151 (lot\# 084M4722V) was dissolved in DMSO to generate a 60 mg/ml stock. This was further diluted to the appropriate working solution with vehicle (10% wt/vol Kleptose HPB in 0.9 %/g NaCl, pH 5.0), filter sterilized, and aliquoted (21 total) into glass vials. Final concentration of DMSO in the working solution was 5% (v/v). Aliquots were stored at 4°C until use when aliquots were brought to room temperature before injection.

Cellular dose response assay {#s3-3}
----------------------------

The doubling time of MV4;11 and K-562 cells were empirically determined by seeding at 4 × 10^4^ cells per well into two 96-well plates. The day after seeding and another three days later an MTS cell proliferation assay (Promega CellTiter-Aqueous One, cat\# G3582) was performed according to the manufacturer's instructions with a 4 hr incubation at 37°C. Absorbance was read at 490 nm and the plate background was subtracted at 650 nm using a plate reader (Molecular Devices, SpectraMax 190) and Softmax Pro data acquisition and analysis software (RRID:[SCR_014240](https://scicrunch.org/resolver/SCR_014240)), version 3.1.2. The doubling time of each cell line was calculated to be 48 hr and 36.2 hr for the MV4;11 and K-562 cell lines, respectively. Doubling time was calculated using the formula (doubling time = incubation time\*ln(2)/ln(second plate average reading/first plate average reading)).

For cellular dose response, MV4;11 and K-562 cells were seeded at 4 × 10^4^ cells per well (non-edge wells) into a 96-well plate and incubated overnight. Cells were treated with serial dilutions of I-BET151 to yield 10 dilutions ranging from 0.001 nM to 1 mM, which differs from the conditions listed in the Registered Report due to solubility limits. I-BET151 doses from 0.001 nM to 100 µM were diluted with medium to give a final DMSO concentration of 0.1%, while the 1 mM concentration gave a final DMSO concentration of 1% due to drug solubility. Both concentrations of DMSO were used to treat control cells in addition to medium alone wells that were used for background subtraction. All conditions were done in technical triplicate. Following an incubation of 3 population doublings of the cell lines, an MTS cell proliferation assay was performed as described for the doubling time experiment. Percent viability was calculated as a percentage of DMSO treated cells after background subtraction (medium only wells). Values for each biological repeat were fit to a four-parameter logistic curve and absolute IC~50~ values were calculated with R software (RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)), version 3.3.2 ([@bib38]).

Gene expression analysis {#s3-4}
------------------------

MV4;11 and K-562 cells were seeded at 1 × 10^5^ cells per well in a 48 well plate in triplicate for each condition and incubated overnight. Cells were then treated with either 500 nM I-BET151 or an equivalent volume of DMSO (final concentration of 0.1% (v/v)) for 6 hr. Cells were then harvested and RNA isolated using the RNAspin mini kit (GE Healthcare, cat\# 25-0500-70) according to manufacturer\'s instructions. RNA concentration and purity was determined (data available at <https://osf.io/n8frz/>) and samples were stored at −80°C until further analyzed. Total RNA was reverse transcribed into cDNA using SuperScript III First-Strand Synthesis System (GE Healthcare, cat\# 27-9261-01) according to manufacturer\'s instructions. qRT-PCR reactions were then performed in technical triplicate using *BCL2* and *B2M*-specific primers (sequences listed in Registered Report \[[@bib18]\]), and SYBR Green PCR Master Mix (ThermoFisher, cat\# 4344463) according to manufacturer's instructions. Reaction volume was 20 µl and consisted of 10 µl 2X SYBR Green PCR Master Mix, 20 µM forward and reverse primers, and 5 µl RNA diluted in water. A negative control without RNA template was also included. PCR cycling conditions were used as follows: \[1 cycle 95°C for 10 min \-- 40 cycles 95°C for 15 s, 60°C 60 s\] using a real-time PCR system (Bio-Rad, DNA Engine Opticon System) and Opticon Monitor Software (Bio-Rad, RRID:[SCR_014241](https://scicrunch.org/resolver/SCR_014241)), version 1.4. *BCL2* transcript levels were normalized to *B2M* levels in each sample and I-BET151 treated samples were compared to DMSO treated samples for each cell line using the ∆∆Ct method.

Animals {#s3-5}
-------

All animal procedures were approved by the University of Pennsylvania Stem Cell and Xenograft Core IACUC\# 803506 and were in accordance with the University of Pennsylvania policies on the care, welfare, and treatment of laboratory animals. Four-week old female NOD-SCID mice (Jackson Laboratory, Stock No: 001303, RRID:[IMSR_JAX:001303](https://scicrunch.org/resolver/IMSR_JAX:001303)) were housed in sterile conditions using high-efficiency particulate arrestance (HEPA)-filtered micro-isolator with 12 hr light/dark cycles, and fed with sterile rodent chow and acidified water *ad libitum*. The mice were housed for approximately 3 weeks before being enrolled in the study.

I-BET151 maximum tolerated dose (MTD) study {#s3-6}
-------------------------------------------

After acclimation, 20 female NOD-SCID mice were conditioned with 30 mg/kg Busulfan (Otsuka America Pharmaceutical, Inc., cat\# NDC 59148-070-90) by intraperitoneal (IP) injection 24 hr prior to injection of MV4;11 cells. Conditioned mice were then intravenously injected via the tail vein with 1 × 10^7^ MV4;11 cells in 0.2 ml sterile vehicle (PBS) (Gibco, Life Technologies, cat\# 14190--136). Mice were inspected daily for signs of distress and the \'Mouse Health Scoring System\' ([@bib7]) was used to record scores for each mouse over the course of the study. At day 21 post-injection, retro-orbital bleeds were collected and analyzed for leukaemia burden by flow cytometry. Detectable disease was not achieved on day 21 and daily inspection continued until day 34 when disease was detected. Animals were then ranked according to disease burden (percent HLA-A,B,C^+^ cells) and randomly assigned to one of four groups using an alternating serpentine method. Group assignment was done by simple randomization. All mice had detectable leukaemia at time of randomization and variability of disease burden was evenly distributed among the four conditions (One-way ANOVA; *F*(3,16) = 0.019, *p*=0.996). After randomization, mice received daily IP injections of vehicle control, 10 mg/kg I-BET151, 20 mg/kg I-BET151, or 30 mg/kg I-BET151 in a volume of 10 ml/kg body weight. Injection volume and dosing was kept constant throughout the treatment period. Mice were inspected daily for the duration of the 21 day drug treatment for decreased spontaneous activity (grooming and ambulation), ruffled fur, weight loss, and loss of hind limb motility. Mice were sacrificed if moribund, received a health-monitoring score of three, or within three days of the last treatment. Upon sacrifice, cardiac puncture was performed to collect the peripheral blood, and then the spleen and both tibias and femora were removed. Splenic cell suspension was made in cold PBS by gently mushing the spleen between two microscopic glass slides. Bones were flushed with cold PBS to isolate bone marrow cells. Red blood cells from samples were lysed using ammonium chloride solution (STEMCELL Technologies, cat\# 07850) according to manufacturer's instructions prior to flow cytometry analysis.

I-BET151 efficacy study {#s3-7}
-----------------------

After one week of acclimation, 28 female NOD-SCID mice were conditioned with Busulfan and injected with MV4;11 cells as described in the MTD study. Five mice died unexpectedly before the first retro-orbital bleed to assess leukaemia burden. The remaining 23 mice were analyzed on day 21 post-injection, with no engraftment detected. Similar to the MTD study, mice were analyzed again two weeks later, with leukaemia burden detected. Animals were then ranked according to disease burden (percent HLA-A,B,C^+^ cells) and randomly assigned to a group using an alternating serpentine method. Designation of vehicle control or I-BET151 to group was done by a simple randomization. All mice had detectable leukaemia at time of randomization and variability of disease burden was evenly distributed among the two conditions (Student's *t*-test; *t*(21) = 0.028, *p*=0.978). After randomization, mice received daily IP injections of vehicle control or 20 mg/kg I-BET151 in a volume of 10 ml/kg body weight. Injection volume and dosing was kept constant throughout the treatment period. Mice were inspected daily and peripheral blood, spleen, and bone marrow cells were isolated upon sacrifice as described for the MTD study.

Flow cytometry analysis {#s3-8}
-----------------------

To assess leukaemia burden in peripheral blood, spleen, and bone marrow cells, a maximum of 10^6^ cells were stained in a sample volume of 50 µl each. 20 µl of APC conjugated anti-human HLA-A,B,C (Biolegend, cat\# 311410, RRID:[AB_314879](https://scicrunch.org/resolver/AB_314879)) or APC conjugated isotype control (Biolegend, cat\# 400220, RRID:[AB_326468](https://scicrunch.org/resolver/AB_326468)) was added and incubated at room temperature for 15 min. CountBright absolute counting beads (Life Technology, cat\# C36950) in 1X FACS lysing solution were added and incubated at room temperature for an additional 15 min. Flow cytometry analysis was performed on a Canto or LSRII (Becton-Dickinson) and analyzed with FlowJo software (Tree Star, Inc., RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)), version 10.1. Gating strategy was described in the Registered Report with a representative example reported in [Figure 4---figure supplement 3A](#fig4s3){ref-type="fig"}.

To assess cell death, a maximum of 10^6^ cells were stained in a sample volume of 50 µl each. 5 µl of APC conjugated anti-human HLA-A,B,C or APC conjugated isotype control was added and incubated at 4°C for 30 min. After washing twice with 1 ml of 1X Binding Buffer and collecting cells by spinning at 300x*g* for 10 min, cells were resuspended in 100 µl of 1X Binding Buffer. 10 µl of Annexin V-FITC (Miltenyi Biotech Ltd, cat\# 130-092-052) was added and incubated at room temperature for 15 min in the dark. After washing twice with 1 ml of 1X Binding Buffer and collecting cells by spinning at 300x*g* for 10 min, cells were resuspended in 500 µl of 1X Binding Buffer. Prior to flow cytometry analysis 5 µl of propidium iodide (PI) (Invitrogen, cat\# P3566) was added. An initial attempt with 7-AAD, which was pre-specified in the Registered Report, was unsuccessful because of an inability to properly compensate, thus PI was substituted. Gating strategy was described in the Registered Report with a representative example reported in [Figure 4---figure supplement 3B](#fig4s3){ref-type="fig"}. Flow cytometry data for this work is also available via Flow Repository (RRID:[SCR_013779](https://scicrunch.org/resolver/SCR_013779); [@bib46]), where it is directly accessible at <https://flowrepository.org/id/FR-FCM-ZY68>.

Immunohistochemistry {#s3-9}
--------------------

Tissues were fixed in 10% buffered formalin (Fisher Scientific, cat\# 23--245685) and subsequently embedded in paraffin. The paraffin blocks were sectioned (5 µm) and stained with mouse anti-human Class 1 HLA-A,B,C antibody (Abcam, cat\# ab70328, RRID:[AB_1269092](https://scicrunch.org/resolver/AB_1269092)) and counterstained with hematoxylin. Staining was performed on a BOND-IIITM instrument (Leica Biosystems, Wetzlar, Germany) using the Bond Polymer Refine Detection System (Leica Biosystems, cat\# DS9800). Heat-induced epitope retrieval was done for 20 min with ER1 solution (Leica Biosystems, cat\# AR9961). Incubation with the HLA-A,B,C antibody was at 1:1200 dilution for 15 min followed by 8 min post-primary step and 8 min incubation with polymer HRP. Then endogenous peroxidase was blocked for 5 min followed by a 10 min incubation with DAB substrate. All staining steps were performed at room temperature with slides washed three times between each step with Bond Wash Solution (Leica Biosystems, cat\# AR9590) or water. A section of human tonsil tissue was processed in parallel as a positive control. Immunostaining was performed by the Pathology Clinical Service Center at the University of Pennsylvania, Perelman School of Medicine.

Statistical analysis {#s3-10}
--------------------

Statistical analysis was performed with R software (RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)), version 3.3.2 ([@bib38]). All data, csv files, and analysis scripts are available on the OSF (<https://osf.io/hcqqy/>). Confirmatory statistical analysis was pre-registered (<https://osf.io/kfx9p/>) before the experimental work began as outlined in the Registered Report ([@bib18]). Data were checked to ensure assumptions of statistical tests were met. A meta-analysis of a common original and replication effect size was performed with a random effects model and the metafor R package ([@bib49]) (<https://osf.io/vfp47/>). The original study data was extracted *a priori* from the published figures by determining the mean and upper/lower error values for each data point. The extracted data were published in the Registered Report ([@bib18]) and were used in the power calculations to determine the sample size for this study.

Deviations from registered report {#s3-11}
---------------------------------

The range of I-BET151 doses used in cellular dose response assay was altered from 0.01 nM to 10 mM listed in the Registered Report to 1 pM to 1 mM reported in this replication attempt. This was due to the solubility of I-BET151 restricting the highest dose that could be tested in this replication attempt (1 mM), which was the same dose tested in the original study. For the *in vivo* experimentation, only female mice were used in this replication attempt rather than a male female split as outlined in the Registered Report. This deviation was caused by an inability to obtain male and female mice from the supplier when the MTD study was performed. To maintain consistency with the MTD study only female mice were utilized in the efficacy study. Furthermore, the time between MV4;11 injection and animal randomization was extended from the 21 days outlined in the Registered Report ([@bib18]) due to undetectable disease burden at this time. Mice were checked for disease burden 2 weeks later to allow additional time for disease manifestation. This occurred in both the MTD and efficacy studies, with disease burden only becoming detectable after this additional time, after which the remaining aspects of the protocol were carried out.

For the cell death flow cytometry analysis an initial attempt using 7-AAD was unsuccessful because of an inability to properly compensate, thus PI, a suitable viability stain, was substituted. Additional materials and instrumentation not listed in the Registered Report, but needed during experimentation are also listed above.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Charles Sawyers as the Senior Editor. Two of the reviewers, Mark Dawson and M Dawn Teare, have agreed to share their names; a third reviewer remains anonymous.

The following issues need to be addressed before acceptance, as outlined below:

1\) The Abstract and text needs to make clear that (and how) the in vivo protocol employed deviated from the original protocol and acknowledge how this might alter the outcome. It seems very important to not give the wrong impression that the xenograft experiments of the original study could not be reproduced, which would easily be the take-home-message after a \"superficial read\" of the current manuscript. To avoid this impression, the authors should clearly highlight the most relevant deviations from the original study (i.e. the alternative conditioning regimen and the reduced I-BET151 dose) in the Abstract.

2\) Complications to interpretation due to other animal health issues should be clearly described. Here, it is not necessary to describe all potential issues in detail in the main text (although perhaps in supplement), but to address the following possibility, raised by reviewer \#1. \"The fact that the reduction in disease burden following IBET treatment closely paralleled the findings reported in the original study yet a survival benefit was not observed here raises the possibility that leukaemia related mortality was not the primary cause for the mortality observed in at least some animals in the IBET treatment arm.\"

Specific examples of places where clarification is in order are given below, as well as some additional suggestions, which have been extracted from the reviews:

Reviewer \#1:

From a reader\'s perspective there is too much emphasis on the statistical testing performed and not enough discussion about the results and how variations to the original study should be interpreted.

For experiments 1) and 2) the general results obtained very much led to the same conclusion. In experiment 1) however, although there was, as previously, a marked difference in sensitivity between MV4;11 (IC50 9 nM) and K562 (unmeasurable), the meta-analysis demonstrated poor reproducibility between the concentrations in the original and reproduced experiments for MV4:11 (IC50 of 26 nM previously).

The main area of discrepancy relates to 3) the in vivo mouse experiment and specifically the efficacy study assessing overall survival. There are a number of methodological aspects of this study that differ substantially to the original study and these are not raised in the Abstract nor discussed adequately in the manuscript. Therapeutically, the dose of the drug was different (less, at 20 vs 30 mg/kg) as was the duration of therapy, with treatment starting at d35 instead of d21 as in the previous study. As disease activity was determined by examination of peripheral blood only and we know that this xenograft model gives disseminated disease, one interpretation could be that the results differed as a lower dose was used in the face of an increased disease bulk. Most importantly technically, the conditioning regime used was markedly different. 30mg/kg of Busulfan is a very different approach to the more conventional strategy of sub-lethal irradiation performed in the original study. The conditioning regime can dramatically alter engraftment kinetics and also the natural history of the disease. This is reflected in this particular case by the fact that one quarter of the mice on this study developed \'solid malignancies\', which I assume to be extramedullary leukaemia. Furthermore 3/12 mice treated with I-BET developed gastrointestinal bloating and (whilst not explicitly described) presumably died for reasons that were independent of the leukaemia burden. This is alluded to by the authors when they state that \"animal health issues were observed beyond the anticipated disease presentation of this model\" but could be stressed more. These important issues impact significantly on an efficacy study that is essentially measuring all cause mortality. The fact that the reduction in disease burden following IBET treatment closely paralleled the findings reported in the original study yet a survival benefit was not observed here raises the possibility that leukaemia related mortality was not the primary cause for the mortality observed in at least some animals in the IBET treatment arm.

All of the above differences would also explain the apparently contradictory finding that, although survival was not impacted, disease bulk was consistently less in the IBET treated arm. A significant issue with the manuscript as currently presented is that the reader is left unaware of these critical details when reading the reproduction. It is essential to communicate this both in the Abstract, in the Results section and when discussing the discrepant results.

The results from the MTD study show that the mice in the 30mg/kg arm had the greatest variation in starting weight amongst all the cohorts. There is a 25% variation in weight between the heaviest and lightest mouse in this cohort whereas the starting weight of the mice in the other cohort\'s vary very little. The initial weight of the mice can contribute substantially to the observed toxicity of any intervention especially conditioning. This variation may be one of the reasons why more toxicity was observed in this cohort.

Reviewer \#2:

The summary assessment of each experiment is not consistently written it states \'did not find a statistically significant\' but the converse is not stated, i.e. \'we did see a statistically significant\'. The summary needs to be consistent. This replication study has been powered from a statistical perspective so this needs to be clear in the Abstract.

Reviewer \#3:

Most experiments reproduce key results of the original study, with the exception of in-vivo treatment studies in the MV4;11 AML xenograft model, where the authors only reproduce the impact on disease burden while impact on overall survival has been observed. For the interpretation of these results it should be noted that the replication study diverged from the original work in several experimental details that might be of relevance.

Overall, the following major points should be considered prior to publication:

In the replication of MV4;11 xenograft experiments several experimental conditions deviate from the original study. Most likely due to a lack of access to an irradiation unit, the authors conditioned NOD/SCID mice with a single dose of busulfan (30 mg/kg i.p. 24 hrs prior to MV4;11 transplantation), which has been reported to lead to comparable engraftment of human CD34+ cord blood cells. Apart from the difference in cell type, the original study by Robert-Richard et al. mainly used other dosing regimens (35 mg/kg 36 hrs prior to injection; or 2 x 25 mg 48/24 hrs prior to injection), which they found to be less toxic. While under these conditions, busulfan and irradiation performed similar in human CD34+ HSC engraftment, one cannot conclude that the used regimen has no impact on the in-vivo growth of MV4;11 AML cells (which, for example, are likely to have a much higher proliferation rate than CD34+ HSCs). In fact, another study (Saland et al., 2015) has documented significant differences in the growth of xenografted MV4;11 cells following irradiation vs. busulfan (20 mg/kg). Although the use of NSG and a lower busulfan dose does not allow for direct conclusions for the present study, these results illustrate how sensitive xenograft models are to conditioning regimens. As most prominent difference, after busulfan conditioning the MV4;11 model turned out to be much delayed compared to the original study, which might be explained by insufficient immunosuppression, toxicity of busulfan or its metabolites on MV4;11 cells, or other experimental differences (which the authors partially summarize in their Discussion). Beyond reducing the overall aggressiveness of the model (and, potentially, promoting a high incidence of xenograft-derived solid tumors, which has been observed by the authors), these altered experimental conditions may also impact the in-vivo responsiveness of MV4;11 cells to I-BET151, which should be discussed. This seems particularly important, since busulfan conditioning is still quite uncommon and the used regimen (30 mg/kg 24 hrs prior to injection) has neither been tested in MV4;11 cells, nor has it been evaluated regarding its impact on treatment responsiveness.

Beyond changing the conditioning protocol, the authors (based on general toxicity studies) also decided to reduce the I-BET151 dose from 30 mg/kg to 20 mg/kg. While this seems reasonable for the specific experiment, the cause for the observed toxicity remains unclear and may (again) be related to the conditioning regimen. Most importantly, the use of a different dosing regimen on its own provides a possible explanation for reduced drug effects in the MV4;11 xenograft model. In fact, in recent work the authors of the original study show that reducing I-BET151 to 10 mg/kg has no impact on survival in this model (Gilan et al., [Figure 3A](#fig3){ref-type="fig"}). Overall, it cannot be assumed that the drug batch was simply more active and, therefore, needed to be reduced to achieve comparable in-vivo activities. While differences in drug batches should always be considered, the reduced tolerability might be due to the used conditioning regimen, and the differences in survival might simply be a consequence of the reduced I-BET151 dose used in this study.

Overall, changes in the conditioning regimen and the use of a lower dose of I-BET151 may substantially alter the in-vivo response of MV4;11 cells and provide (independent) possible explanations for the observed reduction in in-vivo drug activity. In light of these concerns, it seems very important to not give the wrong impression that the xenograft experiments of the original study could not be reproduced, which would easily be the take-home-message after a \"superficial read\" of the current manuscript. To avoid this impression, the authors should clearly highlight the most relevant deviations from the original study (i.e. the alternative conditioning regimen and the reduced I-BET151 dose) in the Abstract. Moreover, these experimental differences should also be discussed more extensively in the Discussion. In the current Discussion, the authors first raise some uncertainties due to missing experimental details, then summarize consistent conditions, and then transition into various possible differences that are hard to control for (which are certainly relevant; differences in MV4;11 culture conditions such as different FBS batches could be added). However, for a comprehensive discussion it seems very adequate to first summarize consistent conditions, then highlight obvious and important differences in experimental design (i.e. different conditioning and different drug dose), and only then discuss additional factors that are not easy to control for.

In summary, the design and execution of this replication study is of high quality, and all necessary changes to the original protocol have been implemented in the best possible way. However, the changes in the design of the xenograft study are substantial and might fully explain the observed differences in in-vivo effects of I-BET151. Due to these differences, the results of the performed xenograft experiments are not fully conclusive with respect to the reproduction of the original study, which should be highlighted more clearly.

10.7554/eLife.25306.015

Author response

*The following issues need to be addressed before acceptance, as outlined below:*

*1) The Abstract and text needs to make clear that (and how) the* in vivo *protocol employed deviated from the original protocol and acknowledge how this might alter the outcome. It seems very important to not give the wrong impression that the xenograft experiments of the original study could not be reproduced, which would easily be the take-home-message after a \"superficial read\" of the current manuscript. To avoid this impression, the authors should clearly highlight the most relevant deviations from the original study (i.e. the alternative conditioning regimen and the reduced I-BET151 dose) in the Abstract.*

We have revised the Abstract to reflect the most relevant deviations between this replication attempt and the original study. We have also included these deviations and expanded discussion on how they might alter the outcome in the main text.

*2) Complications to interpretation due to other animal health issues should be clearly described. Here, it is not necessary to describe all potential issues in detail in the main text (although perhaps in supplement), but to address the following possibility, raised by reviewer \#1. \"The fact that the reduction in disease burden following IBET treatment closely paralleled the findings reported in the original study yet a survival benefit was not observed here raises the possibility that leukaemia related mortality was not the primary cause for the mortality observed in at least some animals in the IBET treatment arm.\"*

We have revised the manuscript to include many of the potential areas of clarification and issues raised in the reviews. Specifically, for the possibility raised by reviewer \#1, we included this possibility in an additional paragraph after describing the results of the in vivo experiment.

*Specific examples of places where clarification is in order are given below, as well as some additional suggestions, which have been extracted from the reviews:*

*Reviewer \#1:*

*From a reader\'s perspective there is too much emphasis on the statistical testing performed and not enough discussion about the results and how variations to the original study should be interpreted.*

*For experiments 1) and 2) the general results obtained very much led to the same conclusion. In experiment 1) however, although there was, as previously, a marked difference in sensitivity between MV4;11 (IC50 9 nM) and K562 (unmeasurable), the meta-analysis demonstrated poor reproducibility between the concentrations in the original and reproduced experiments for MV4:11 (IC50 of 26 nM previously).*

*The main area of discrepancy relates to 3) the* in vivo *mouse experiment and specifically the efficacy study assessing overall survival. There are a number of methodological aspects of this study that differ substantially to the original study and these are not raised in the Abstract nor discussed adequately in the manuscript. Therapeutically, the dose of the drug was different (less, at 20 vs 30 mg/kg) as was the duration of therapy, with treatment starting at d35 instead of d21 as in the previous study. As disease activity was determined by examination of peripheral blood only and we know that this xenograft model gives disseminated disease, one interpretation could be that the results differed as a lower dose was used in the face of an increased disease bulk. Most importantly technically, the conditioning regime used was markedly different. 30mg/kg of Busulfan is a very different approach to the more conventional strategy of sub-lethal irradiation performed in the original study. The conditioning regime can dramatically alter engraftment kinetics and also the natural history of the disease. This is reflected in this particular case by the fact that one quarter of the mice on this study developed \'solid malignancies\', which I assume to be extramedullary leukaemia. Furthermore 3/12 mice treated with I-BET developed gastrointestinal bloating and (whilst not explicitly described) presumably died for reasons that were independent of the leukaemia burden. This is alluded to by the authors when they state that \"animal health issues were observed beyond the anticipated disease presentation of this model\" but could be stressed more. These important issues impact significantly on an efficacy study that is essentially measuring all cause mortality. The fact that the reduction in disease burden following IBET treatment closely paralleled the findings reported in the original study yet a survival benefit was not observed here raises the possibility that leukaemia related mortality was not the primary cause for the mortality observed in at least some animals in the IBET treatment arm.*

*All of the above differences would also explain the apparently contradictory finding that, although survival was not impacted, disease bulk was consistently less in the IBET treated arm. A significant issue with the manuscript as currently presented is that the reader is left unaware of these critical details when reading the reproduction. It is essential to communicate this both in the Abstract, in the Results section and when discussing the discrepant results.*

We agree that there are many aspects a reader needs to consider when interpreting this study, just like any individual study. We have revised the manuscript to include the points raised here, specifically including discussion on the deviation in dose and conditioning used and the impact this could potentially have had on engraftment kinetics, disease progression, and determining survival benefit. We have also clarified in the text that the gastrointestinal bloating was observed at the time of sacrifice and expanding discussion about the solid tumors, which as this review suggests is likely extramedullary disease.

*The results from the MTD study show that the mice in the 30mg/kg arm had the greatest variation in starting weight amongst all the cohorts. There is a 25% variation in weight between the heaviest and lightest mouse in this cohort whereas the starting weight of the mice in the other cohort\'s vary very little. The initial weight of the mice can contribute substantially to the observed toxicity of any intervention especially conditioning. This variation may be one of the reasons why more toxicity was observed in this cohort.*

We agree that variation in the initial weight of the mice could be a reason for observed toxicity, but in the case of the 30 mg/kg cohort, the lightest mouse did not have any observed weight loss throughout the course of the MTD study or have a health monitoring score that justified euthanasia. The remaining four mice had weights with variation similar to the other cohorts; however two of those mice had to be euthanized, which defined the MTD for the study.

*Reviewer \#2:*

*The summary assessment of each experiment is not consistently written it states \'did not find a statistically significant\' but the converse is not stated, i.e. \'we did see a statistically significant\'. The summary needs to be consistent. This replication study has been powered from a statistical perspective so this needs to be clear in the Abstract.*

We have revised the Abstract to provide a balanced summary assessment. We included 'statistically significant' for the *BCL2* expression analysis, since we followed through on the confirmatory analysis that was powered from a statistical perspective. However, we did not revise the analysis of IC~50~ values since this was an exploratory analysis.

*Reviewer \#3:*

*Most experiments reproduce key results of the original study, with the exception of in-vivo treatment studies in the MV4;11 AML xenograft model, where the authors only reproduce the impact on disease burden while impact on overall survival has been observed. For the interpretation of these results it should be noted that the replication study diverged from the original work in several experimental details that might be of relevance.*

*Overall, the following major points should be considered prior to publication:*

*In the replication of MV4;11 xenograft experiments several experimental conditions deviate from the original study. Most likely due to a lack of access to an irradiation unit, the authors conditioned NOD/SCID mice with a single dose of busulfan (30 mg/kg i.p. 24 hrs prior to MV4;11 transplantation), which has been reported to lead to comparable engraftment of human CD34+ cord blood cells. Apart from the difference in cell type, the original study by Robert-Richard et al. mainly used other dosing regimens (35 mg/kg 36 hrs prior to injection; or 2 x 25 mg 48/24 hrs prior to injection), which they found to be less toxic. While under these conditions, busulfan and irradiation performed similar in human CD34+ HSC engraftment, one cannot conclude that the used regimen has no impact on the in-vivo growth of MV4;11 AML cells (which, for example, are likely to have a much higher proliferation rate than CD34+ HSCs). In fact, another study (Saland et al., 2015) has documented significant differences in the growth of xenografted MV4;11 cells following irradiation vs. busulfan (20 mg/kg). Although the use of NSG and a lower busulfan dose does not allow for direct conclusions for the present study, these results illustrate how sensitive xenograft models are to conditioning regimens. As most prominent difference, after busulfan conditioning the MV4;11 model turned out to be much delayed compared to the original study, which might be explained by insufficient immunosuppression, toxicity of busulfan or its metabolites on MV4;11 cells, or other experimental differences (which the authors partially summarize in their Discussion). Beyond reducing the overall aggressiveness of the model (and, potentially, promoting a high incidence of xenograft-derived solid tumors, which has been observed by the authors), these altered experimental conditions may also impact the in-vivo responsiveness of MV4;11 cells to I-BET151, which should be discussed. This seems particularly important, since busulfan conditioning is still quite uncommon and the used regimen (30 mg/kg 24 hrs prior to injection) has neither been tested in MV4;11 cells, nor has it been evaluated regarding its impact on treatment responsiveness.*

We have revised the manuscript to include the points raised in here, specifically including discussion on the deviation in the conditioning used and the impact this could potentially have had on engraftment kinetics, disease progression, and responsiveness of the MV4;11 cells to I-BET151, especially considering the impact busulfan has on this model is not fully understood.

*Beyond changing the conditioning protocol, the authors (based on general toxicity studies) also decided to reduce the I-BET151 dose from 30 mg/kg to 20 mg/kg. While this seems reasonable for the specific experiment, the cause for the observed toxicity remains unclear and may (again) be related to the conditioning regimen. Most importantly, the use of a different dosing regimen on its own provides a possible explanation for reduced drug effects in the MV4;11 xenograft model. In fact, in recent work the authors of the original study show that reducing I-BET151 to 10 mg/kg has no impact on survival in this model (Gilan et al., [Figure 3A](#fig3){ref-type="fig"}). Overall, it cannot be assumed that the drug batch was simply more active and, therefore, needed to be reduced to achieve comparable in-vivo activities. While differences in drug batches should always be considered, the reduced tolerability might be due to the used conditioning regimen, and the differences in survival might simply be a consequence of the reduced I-BET151 dose used in this study.*

We agree that changing the dose of I-BET151 could impact the efficacy of the drug independent of the impact other experimental factors might have as well. We have revised the manuscript to highlight this and discuss it in context of other work by authors of the original study who recently reported I-BET151 administered at 10 mg/kg had no impact on survival in a MLL-AF9 leukemia mouse model (Gilan et al., 2016), while I-BET151 administered at 15 mg/kg did provide a survival benefit in a mouse model of NPM1c AML, albeit with a smaller effect size (Dawson et al., 2014).

*Overall, changes in the conditioning regimen and the use of a lower dose of I-BET151 may substantially alter the in-vivo response of MV4;11 cells and provide (independent) possible explanations for the observed reduction in in-vivo drug activity. In light of these concerns, it seems very important to not give the wrong impression that the xenograft experiments of the original study could not be reproduced, which would easily be the take-home-message after a \"superficial read\" of the current manuscript. To avoid this impression, the authors should clearly highlight the most relevant deviations from the original study (i.e. the alternative conditioning regimen and the reduced I-BET151 dose) in the Abstract. Moreover, these experimental differences should also be discussed more extensively in the Discussion. In the current Discussion, the authors first raise some uncertainties due to missing experimental details, then summarize consistent conditions, and then transition into various possible differences that are hard to control for (which are certainly relevant; differences in MV4;11 culture conditions such as different FBS batches could be added). However, for a comprehensive discussion it seems very adequate to first summarize consistent conditions, then highlight obvious and important differences in experimental design (i.e. different conditioning and different drug dose), and only then discuss additional factors that are not easy to control for.*

We have revised the Abstract to reflect the most relevant deviations between this replication attempt and the original study. We have also reordered the experimental differences as suggested and included these deviations and expanded discussion on how they might alter the outcome in the main text.

In summary, the design and execution of this replication study is of high quality, and all necessary changes to the original protocol have been implemented in the best possible way. However, the changes in the design of the xenograft study are substantial and might fully explain the observed differences in in-vivo effects of I-BET151. Due to these differences, the results of the performed xenograft experiments are not fully conclusive with respect to the reproduction of the original study, which should be highlighted more clearly.

We agree that there are many aspects a reader needs to consider when interpreting this study, just like any individual study and have revised the manuscript to address the points raised in these reviews.
